Stabilized Exendin-4 compounds

Details Stabilized Exendin-4 compounds Stabilized Exendin-4 compounds

2003-10-02

2009-06-09

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S300000, C530S308000, C530S324000

Reexamination Certificate

active

07544657

ABSTRACT:
The present invention disclosed compositions comprising a stabilized Exendin-4 (1-39) and related compounds. The invention describes stabilized Exendin-4 agonists that include at least one modified amino acid residue particularly at positions Gln 13, Met14, Trp25, or Asn28 of the Exendin-4 (1-39) molecule. Disclosed are preferred modifications of deaminated, hydrolyzed, oxidized, or isomerized reaction products of the specified amino acid residues corresponding to the same positions in the Exendin-4 molecule. The invention also relates to methods of making and using the stabilized Exendin compounds, such as for the treatment of diabetes.

REFERENCES:
patent: 5407609 (1995-04-01), Tice et al.
patent: 5424286 (1995-06-01), Eng
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5654008 (1997-08-01), Herbert et al.
patent: 5670360 (1997-09-01), Thorens
patent: 5846747 (1998-12-01), Thorens et al.
patent: 5846937 (1998-12-01), Drucker
patent: 6006753 (1999-12-01), Efendic
patent: 6051689 (2000-04-01), Thorens
patent: 6110703 (2000-08-01), Egel-Mitani et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6268343 (2001-07-01), Knudsen et al.
patent: 6271241 (2001-08-01), DiSimone et al.
patent: 6277819 (2001-08-01), Efendic
patent: 6284725 (2001-09-01), Coolidge et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6344180 (2002-02-01), Holst et al.
patent: 6358924 (2002-03-01), Hoffmann
patent: 6384016 (2002-05-01), Kaarsholm
patent: 6388053 (2002-05-01), Galloway et al.
patent: 6410508 (2002-06-01), Isales et al.
patent: 6528486 (2003-03-01), Larsen et al.
patent: 2004/0106547 (2004-06-01), Larsen et al.
patent: 2007/0111940 (2007-05-01), Larsen et al.
patent: 19637230 (1998-03-01), None
patent: WO9318786 (1993-09-01), None
patent: WO9805351 (1998-02-01), None
patent: WO9808531 (1998-03-01), None
patent: WO9808873 (1998-03-01), None
patent: WO9819698 (1998-05-01), None
patent: WO9830231 (1998-07-01), None
patent: WO9835033 (1998-08-01), None
patent: WO9839022 (1998-09-01), None
patent: WO9907404 (1999-02-01), None
patent: WO9925727 (1999-05-01), None
patent: WO9925728 (1999-05-01), None
patent: WO9940788 (1999-08-01), None
patent: WO9943708 (1999-09-01), None
patent: WO9946283 (1999-09-01), None
patent: WO0066629 (2000-11-01), None
patent: WO0104156 (2001-01-01), None
Goke et al., J. Biol. Chem. 1993, 268, 19650-19655.
Byrne et al., “Inhibitory Effects of Hyperglycaemia on Fed Jejunal Motility: Potential Role of Hyperinsulinaemia,”Euro. J. Clin. Invest. 28:72-78 (1998).
Chen et al., “Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard,”J. Biol. Chem. 272:4108-4115 (1997).
D'Alessio et al., “Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal,”J. Clin. Invest. 93:2263-2266 (1994).
Drucker, D., “Glucagon-Like Peptides,”Diabetes47:159-169 (1998).
Drucker, D., “Minireview: The Glucagon-Like Peptides,”Endocrinology521-527. (2001).
Göke et al., “Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells,”J. Biol. Chem. 268:19650-19655 (1993).
Greig et al., “Once Daily Injection of Exendin-4 to Diabetic Mice Achieves Long-Term Beneficial Effects on Blood Glucose Concentrations.”Diabetologia42:45-50 (1999).
Merrifield, B., “Solid Phase Synthesis.”Science232:341-347 (1986).
Nauck et al., “Glucagon-Like Peptide 1 and its Potential in the Treatment of Non-Insulin-Dependent Diaetes Mellitus,”Horm. Metab. Res. 29:411-416 (1997).
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,”J. Mol. Biol. 48:443-453 (1970).
Ørskov, C., “Glucagon-like Peptide-1, a New Hormone of the Entero-insular Axis,”Diabetologia35:701-711 (1992).
Pederson et al., “Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide.”Diabetes47:1253-1258 (1998).
Pohl et al., “Molecular Cloning of the Heloderman and Exendin-4 cDNAs in the Lizard,”J. Biol. Chem. 273:9778-9784 (1998).
International Search Report from PCT/DK03/00651 dated Oct. 2, 2003.
International Preliminary Examination Report from PCT/DK03/00651 dated Jan. 31, 2005.

Affiliated with

Also associated with

Rating

Stabilized Exendin-4 compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stabilized Exendin-4 compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized Exendin-4 compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4146125